X4 Pharmaceuticals
X4 Pharmaceuticals' revenue rose 150.0% to $6 million in fiscal 2025. Its operating margin was −1,336.7%, up from −1,400.0% a year earlier. Free cash flow was −$86 million. The diluted share count rose 531.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What X4 Pharmaceuticals does
X4 Pharmaceuticals is a biopharmaceutical company that develops and sells treatments for rare blood diseases. Its main asset is mavorixafor, a once-daily capsule that blocks a receptor called CXCR4. It has one approved product, XOLREMDI (mavorixafor), which has FDA accelerated approval in the United States for patients 12 and older with WHIM syndrome, a rare inherited immune disorder. Revenue comes from sales of XOLREMDI.
Its main effort is a global Phase 3 trial, called 4WARD, of mavorixafor in chronic neutropenia, a condition of low white blood cell counts that leads to repeated or serious infections. The trial aims to enroll up to 176 patients, with full enrollment targeted for the third quarter of 2026 and top-line data expected in the second half of 2027. The FDA has granted the drug Fast Track designation for this use. If the trial succeeds, the company plans to commercialize mavorixafor for chronic neutropenia on its own in regions with clear regulatory paths, and it may look at partnerships.
In August 2025 its chief executive and chief financial officer stepped down. During 2025 it carried out two restructurings, which led to a reduction in head count of about 65%. As of December 31, 2025, it had 45 full-time employees, 29 in research and development and 16 in general and administrative roles.
Its biggest risks, as it describes them
- It has lost money since it began and needs more funding, which could dilute shareholders or limit operations.
- It depends almost entirely on mavorixafor, and the chronic neutropenia market may be smaller than it expects.
- The 4WARD trial may fail to support its claims, and regulatory review is long and unpredictable.
- It could lose patent rights if it fails to comply with its license agreements.
- Its relationships with partners and licensors, including Genzyme, could change or end.
Income statement
X4 Pharmaceuticals lost money in fiscal 2025: a net loss of $79 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 82 | 122 | 114 | 102 | 253 |
| Debt incl. finance leases | 32 | 32 | 55 | 75 | 75 |
| Net debt (negative means net cash) | −49 | −89 | −59 | −27 | −178 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.5x | 0.4x | 1.1x | 3.4x | 0.4x |
| Interest coverage | −23.4x | −21.9x | −18.6x | −4.2x | −9.8x |
| Current ratio | 6.3x | 5.8x | 5.3x | 3.4x | 10.2x |
| Quick ratio | 6.3x | 5.8x | 5.3x | 3.3x | 10.1x |
Cash flow
Projections
Project X4 Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought X4 Pharmaceuticals shares on the open market, and 3 insiders sold $428,889.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Adam R CraigExecutive Chairman, Director | Sold | 47,436 | $4.44 | $210,616 | Form 4 |
| Aug 12, 2026 | John VolponePresident | Sold | 24,576 | $4.44 | $109,117 | Form 4 |
| Jun 30, 2026 | David KirskeChief Financial Officer | Sold | 8,543 | $4.26 | $36,393 | Form 4 |
| May 12, 2026 | David KirskeChief Financial Officer | Sold | 16,961 | $4.29 | $72,763 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 3 of 9 |
| Rule of 40 | — | — | −1,167.2% |
| Altman Z'' | −10.51 | −9.40 | −1.48 |
| Accruals ratio | −3.1% | 63.6% | 2.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 2 of 8 | 2 of 8 | 3 of 9 |
Compare
Put X4 Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals | FY25 | 150.0% | −1,336.7% | −1,317.2% | — | — | 3 | |
| Fate Therapeutics | FY25 | −51.2% | −2,222.4% | −1,685.8% | — | — | — | Compare |
| Korro Bio | FY25 | 181.5% | −1,906.4% | −1,237.2% | — | — | — | Compare |
| Whitehawk Therapeutics | FY25 | −72.5% | −1,601.1% | −1,371.4% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 6 |
| Revenue growth | — | — | — | — | — | −100.0% | — | — | — | 150.0% |
| Gross profit | — | — | — | — | — | — | 0 | 0 | 2 | 1 |
| Research and development | 18 | 17 | 20 | 30 | 42 | 51 | 61 | 72 | 82 | 73 |
| Operating income | −24 | −22 | −29 | −52 | −60 | −85 | −88 | −108 | −36 | −87 |
| Net income | −23 | −22 | −33 | −53 | −62 | −89 | −94 | −101 | −37 | −79 |
| Diluted EPS (US$) | −1,343.70 | −1,637.40 | −2,374.50 | −138.90 | −92.70 | −119.70 | −45.60 | −17.07 | −5.59 | −1.87 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 6 | 7 | 42 |
| Cash flow | ||||||||||
| Cash from operations | −22 | −21 | −25 | −48 | −59 | −71 | −77 | −96 | −131 | −86 |
| Capital expenditure | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −22 | −22 | −25 | −48 | −60 | −72 | −77 | −97 | −131 | −86 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 0 | 1 | 2 | 5 | 6 | 5 | 9 | 8 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 15 | 27 | 8 | 126 | 79 | 82 | 122 | 114 | 102 | 253 |
| Debt incl. finance leases | — | — | 10 | 20 | 32 | 32 | 32 | 55 | 75 | 75 |
| Total assets | — | 81 | 10 | 161 | 123 | 117 | 156 | 147 | 146 | 290 |
| Total liabilities | — | 22 | 22 | 32 | 50 | 53 | 82 | 96 | 124 | 104 |
| Shareholders' equity | −23 | −44 | −77 | 129 | 73 | 64 | 74 | 51 | 22 | 186 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | 69.3% | 11.4% |
| Operating margin | — | — | — | — | −1,995.8% | — | — | — | −1,400.0% | −1,336.7% |
| Net margin | — | — | — | — | −2,071.0% | — | — | — | −1,440.4% | −1,218.5% |
| Free cash flow margin | — | — | — | — | −2,006.0% | — | — | — | −5,047.2% | −1,317.2% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | −1,167.2% |
| Return on capital | — | — | — | — | −190.6% | −322.3% | — | — | — | — |
| Return on equity | — | — | — | −202.6% | −61.5% | −129.3% | −135.6% | −161.7% | −102.3% | −76.0% |
| Return on assets | — | — | −73.0% | −61.9% | −43.8% | −73.9% | −68.8% | −66.8% | −25.5% | −36.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |